Sign in to view content

Abicipar Phase 2 MAPLE Trial Supports Improved Safety for Patients with nAMD Following a Modified Manufacturing Process

Raj K. Maturi, MD

Video
Published 2019

Related

Interim Results of the Phase 1-2 PRISM Trial Evaluating 4D-150 a Dual-Transgene Intravitreal Genetic Medicine for Neovascular (Wet) Age-Related Macular Degeneration
Christine Kay, MD
Annual Meeting Talks
2023
Combination Therapy With Intravitreal Nesvacumab+Aflibercept in Diabetic Macular Edema: The Phase 2 RUBY Trial
Jeffrey S. Heier, MD
Annual Meeting Talks
2018
Should We Ever Consider Stopping Treatment for Neovascular AMD?
Rahul N. Khurana, MD, FASRS
Updates from the Field
2020

Category: AMD-Neovascular

See more